Item Type | Name |
Concept
|
Lipoprotein Lipase
|
Concept
|
Lipoprotein(a)
|
Academic Article
|
Age-dependence of the relationship between adiposity and serum low density lipoprotein cholesterol in men.
|
Academic Article
|
Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia.
|
Academic Article
|
Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals.
|
Academic Article
|
Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women.
|
Academic Article
|
What kinds of data should be available to probe the effects of nutrients, food supplements or vitamins on serum lipoprotein levels and/or atherosclerosis?
|
Academic Article
|
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
|
Academic Article
|
Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women.
|
Academic Article
|
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
|
Academic Article
|
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
|
Academic Article
|
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.
|
Academic Article
|
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
|
Academic Article
|
Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol.
|
Academic Article
|
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
|
Academic Article
|
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
|
Academic Article
|
High-density lipoprotein metabolism: potential therapeutic targets.
|
Academic Article
|
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
|
Academic Article
|
Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals.
|
Academic Article
|
Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes.
|
Academic Article
|
Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
|
Academic Article
|
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
|
Academic Article
|
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
|
Academic Article
|
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
|
Academic Article
|
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
|
Academic Article
|
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials.
|
Academic Article
|
Novel targets that affect high-density lipoprotein metabolism: the next frontier.
|
Academic Article
|
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk.
|
Academic Article
|
Focusing on high-density lipoprotein for coronary heart disease risk reduction.
|
Academic Article
|
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.
|
Academic Article
|
Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction.
|
Academic Article
|
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
|
Academic Article
|
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
|
Academic Article
|
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
|
Academic Article
|
Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence.
|
Academic Article
|
Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprotein cholesterol ratio in patients without diabetes mellitus.
|
Academic Article
|
Drugs in development for management of lipoprotein disorders.
|
Academic Article
|
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
|
Academic Article
|
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
|
Academic Article
|
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
|
Academic Article
|
Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes.
|
Academic Article
|
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
|
Academic Article
|
Non-high-density lipoprotein cholesterol: the forgotten therapeutic target.
|
Academic Article
|
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
|
Academic Article
|
Gemfibrozil treatment in patients with elevated lipoprotein a: a pilot study.
|
Academic Article
|
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
|
Academic Article
|
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice.
|
Academic Article
|
The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.
|
Academic Article
|
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.
|
Academic Article
|
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
|
Academic Article
|
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
|
Academic Article
|
Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients.
|
Academic Article
|
Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067.
|
Academic Article
|
Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women.
|
Academic Article
|
Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure?
|
Academic Article
|
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.
|
Academic Article
|
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned.
|
Academic Article
|
Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy.
|
Academic Article
|
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
|
Academic Article
|
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
|
Academic Article
|
Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study.
|
Academic Article
|
Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis.
|
Academic Article
|
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
|
Academic Article
|
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
|
Academic Article
|
Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C.
|
Academic Article
|
The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature.
|
Academic Article
|
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
|
Academic Article
|
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
|
Academic Article
|
Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy.
|
Academic Article
|
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
|
Academic Article
|
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.
|
Academic Article
|
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition.
|